Presentation Operator Thank you for standing by, and welcome to Revolution Medicines Conference Call. Today's program is being recorded. [Operator Instructions] I'd now like to introduce your host for today's program, Ryan Asay, Senior Vice President of Corporate Affairs. Please go ahead. Ryan AsaySenior Vice President of Corporate Affairs Thank you, and welcome, everyone, to this afternoon's webcast. Joining me on today's call are Dr. Mark Goldsmith, Revolution Medicines' Chairman and Chief Executive O ...

Presentation Operator Thank you for standing by, and welcome to Revolution Medicines Conference Call. Today's program is being recorded. [Operator Instructions] I'd now like to introduce your host for today's program, Ryan Asay, Senior Vice President of Corporate Affairs. Please go ahead. Ryan AsaySenior Vice President of Corporate Affairs Thank you, and welcome, everyone, to this afternoon's webcast. Joining me on today's call are Dr. Mark Goldsmith, Revolution Medicines' Chairman and Chief Executive O ...

业绩总结 - 2024年净销售额为272,751,967美元，较2023年的258,857,380美元增长5.5%[5] - 2024年毛利为67,267,160美元，较2023年的61,772,306美元增长8.1%[5] - 2024年运营利润为20,149,004美元，较2023年的17,033,224美元增长18.5%[5] - 2024年持续经营的净收入为13,215,524美元，较2023年的11,780,351美元增长12.2%[5] - 2024年总净损失为8,529,217美元，而2023年则为8,585,002美元[5] 负面信息 - 2024年来自已终止业务的净损失为21,744,741美元，较2023年的3,195,349美元显著增加[5] 市场展望 - 2025年Eberhard的市场收入分布中，重型运输占31%，非轮式公司占15%[16] - Velvac的市场收入中，重型卡车占47%，分销占24%[20] - Big 3的市场收入中，货架占37%，设计占10%[23] 新策略 - 公司致力于消除官僚主义，专注于提高业绩和增加股东价值[6]